Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANET: Pembrolizumab Adjuvant in Early-stage TNBC With Residual Disease
NCT07486687Phase 3Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2026
- Primary completion
- Apr 2032
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07486687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486687.